---
title: "Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286245980.md"
description: "Aprea Therapeutics, Inc. reported Q1 2026 results with $0 revenue and a net loss of $(3.29M), an improvement from $(3.93M) in Q1 2025. Diluted EPS was $(0.22), up from $(0.66) YoY. Clinical progress includes APR-1051 showing partial responses in endometrial cancer. The company is prioritizing ATRN-119 combination studies and expects cash to fund operations into Q1 2028 after recent equity raises."
datetime: "2026-05-13T10:51:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286245980.md)
  - [en](https://longbridge.com/en/news/286245980.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286245980.md)
---

# Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary

Aprea Therapeutics, Inc. reported first-quarter 2026 results showing no revenue and a narrower net loss versus the year-ago quarter. The company recorded revenue of $0 and a net loss of $(3.29M) for Q1 2026, with diluted loss per share of $(0.22), an improvement versus the prior-year quarter.

**Financial Highlights**

-   Revenue was $0 for Q1 2026, down from $162,463 in Q1 2025 (‑$162.5K YoY).
-   Net income was a net loss of $(3.29M) for Q1 2026, improved from a net loss of $(3.93M) in Q1 2025 (improvement of $0.64M YoY).
-   Diluted earnings per share was $(0.22) for Q1 2026, versus $(0.66) in Q1 2025 (improvement of $0.44 YoY).

**Business Highlights**

-   Clinical progress: APR-1051 showed early proof-of-concept with confirmed partial responses in PPP2R1A‑mutated endometrial cancer; dose escalation continues in the 300–500mg range.
-   Pipeline updates: ATRN‑119 completed monotherapy dose escalation with an RP2D of 1,100mg and is being evaluated in combination strategies; APR‑1602 is slated to enter IND‑enabling studies in late 2026.
-   Operational shift: The company is winding down ABOYA‑119 monotherapy work to prioritize ATRN‑119 combination studies and investigator‑initiated collaborations.
-   Development plan: The ACESOT‑1051 expansion aims to enroll at least 50 patients with uterine serous carcinoma and platinum‑resistant ovarian cancer to refine the biomarker strategy.
-   Balance sheet: Cash on hand is expected to fund operations into Q1 2028 following significant equity raises in private placements during Jan–Mar 2026 to support clinical development.

Original SEC Filing: Aprea Therapeutics, Inc. \[ APRE \] - 10-Q - May. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [APRE.US](https://longbridge.com/en/quote/APRE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Aprea Therapeutics Q1 net loss narrows as R&D expenses fall](https://longbridge.com/en/news/286243183.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says](https://longbridge.com/en/news/286290495.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)